PRESS RELEASES

February 2, 2017

Maryland Cancer Discovery Incubator Finalists Announced


January 5, 2017

Immunomic Therapeutics Announces Scientific Advisory Board Additions


December 20, 2016

Astellas’ peanut allergies DNA vaccine gains an FDA fast-track designation


December 14, 2016

Immunomic Therapeutics Announces Board Addition


November 22, 2016

Immunomic Therapeutics Announces Expansion of IP Portfolio


November 14, 2016

Tech Council of Maryland Announces Chairman and New Board Members


November 8, 2016

Immunomic Therapeutics Gives Back to Maryland Biotech Community


October 4, 2016

Immunomic Therapeutics (ITI) and Nature Technology Corporation (NTC) Jointly Announce Expanded Agreement


August 2, 2016

BHI Appoints New Board Members From Immunomic, Montgomery County


May 23, 2016

Immunomix CEO and Oncosec VP to Host Fireside Chat


May 16, 2016

Immunomic Therapeutics (ITI) Named “Company of the Year” by the Tech Council of Maryland


April 25, 2016

Immunomic Therapeutics (ITI) Delivering Closing Keynote Address at Wharton DC Innovation Summit


April 18, 2016

Immunomic Therapeutics (ITI) Featured at Maryland Regional Biotech Forum


March 29, 2016

Immunomic Therapeutics (ITI) and Lysosomal Associated Membrane Protein (LAMP) Based Nucleic Acid Immunotherapy Featured At 2016 World Vaccine Congress


January 14, 2016

Novel Platform Technology for Allergy & Cancer Immunology Featured at Biotech Showcase 2016


January 12, 2016

Media Invited: Immunomic Therapeutics, Inc. talks vital vaccine technology advancement at Biotech Showcase 2016


November 11, 2015

Johns Hopkins University & Immunomic Therapeutics, Inc. Tech Transfer Celebration


October 9, 2015

Immunomic Therapeutics and Astellas Pharma announce exclusive licensing agreement for LAMP-vax platform to prevent and treat allergies


August 28, 2015

Immunomic Therapeutics, Inc. to Present at Skin Vaccination Summit in Switzerland


June 15, 2015

ITI Taps Micronaut to Visually Demonstrate Its LAMP-vax Programs


June 3, 2015

Immunomic Therapeutics, Inc. CEO, William Hearl, Ph.D. to Speak at 2015 BIO International Convention


May 13, 2015

Immunomic Therapeutics, Inc. Awarded $1.2M Department of Defense Grant for Development of ARA-LAMP-vax Peanut Allergy Vaccine


May 6, 2015

Immunomic Therapeutics Names Louise Peltier as Vice President, Regulatory Affairs


May 4, 2015

Immunomic Therapeutics Appoints Eric Winzer as Chief Financial Officer


April 2, 2015

Immunomic Therapeutics to Present at 15th Annual World Vaccine Congress


March 31, 2015

ITI Awarded SBIR Grant From NIH For Nanoplasmid Peanut Allergy Vaccine Development


March 25, 2015

ITI Receives Positive Feedback From FDA


March 9, 2015

ITI Present at BIO-Europe Annual Conference


March 3, 2015

ITI Explains Proprietary LAMP-vax Platform in Nature Advertorial Supplement


Feb 20, 2015

ITI to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 AAAAI Meeting


Feb 10, 2015

ITI Appoints Vice President of Operations


Jan 29, 2015

Astellas Pharma and Immunomic Therapeutics Announce Exclusive License for JRC2-LAMP-vax


Jan 09, 2015

ITI To Present at Biotech Showcase 2015


Dec 19, 2014

Bioject and Immunomic Therapeutics, Inc.


Dec 05, 2014

Significant Headway in Regulatory Interactions in Japan


Oct 28, 2014

Successful Completion of Series A Preferred Financing Round


Oct 01, 2014

ITI Filing an IND for a Phase II Study


Sep 17, 2014

ITI Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy


Aug 21, 2014

Relief for Allergy Sufferers Finally in Sight – Phase IC


Jun 29, 2014

Immunomic Therapeutics Engages Newport Coast Securities, Inc.


Jun 28, 2014

String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline


Jun 17, 2014

ITI Announces Significant Strides in Peanut Allergy Vaccine Development


May 19, 2014

ITI CEO Appointed to Panel at Prestigious Future in Review Conference


Apr 03, 2014

ITI Announces Data Analysis of Phase IB Study to Treat Japanese Red Cedar Allergy


Nov 07, 2013

ITI’s Process Development Laboratory at Hershey is Now Operational


Oct 22, 2013

ITI’s Medical Monitor, Dr. Lawrence Weiner, to Present at the 2013 ACAAI Annual Scientific Meeting


Jul 12, 2013

ITI Closes $3 Million Debt Pre-Series B Round


Jun 19, 2013

Myriad Supreme Court Case Has Promising Outcome for Immunomic Therapeutics


Apr 24, 2013

ITI Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy


Apr 10, 2013

ITI Announces Bernard C. Rudnick’s Nomination to the Board of Directors


Mar 25, 2013

ITI Has Generated More Than $6.5 Million in Funding To Date


Feb 22, 2013

ITI Receives Notice of Issuance for Chimeric Vaccines Patent


Jan 24, 2013

ITI Completes Patient Enrollment into Phase I protocol


Nov 5, 2012

Entering First Patients into Phase I protocol


Oct 25, 2012

New Process Development Laboratory at HCAR


Aug 2, 2012

Immunomic Therapeutics Receives Notice of Patent Allowance For Chimeric Vaccines, a Core Component of LAMP-Vax™ Vaccines


May 24, 2012

Immunomic Therapeutics’ CEO, Dr. William G. Hearl, to Present at the 2012 BIO International Convention in June


May 2, 2012

Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRCLAMP- Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy


May 2, 2012

Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRCLAMP- Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy in JAPANESE


Apr 24, 2012

Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy


March 26, 2012

Filing of IND for JRC-LAMP-vax


Jan 9, 2012

Iti Secures Phase I Funding For Japanese Red Cedar Lamp Vaccine


Jan 1, 2012

LAMP Technology Promises Next Generation Vaccines to Improving Human Health


Apr 1, 2011

Immunomic Therapeutics Shareholders Elect Board, Barry McDonald as Chair.